Pasithea Therapeutics says FDA cleared IND for PAS-004 in NF1-associated cutaneous neurofibromas

Pasithea Therapeutics says the FDA cleared its Investigational New Drug application for PAS-004, a macrocyclic MEK inhibitor, for treating NF1-associated cutaneous neurofibromas, allowing the company to initiate clinical development for the indication.

Detected & updated continuously · Source: Nebula